FLGT
Fulgent Genetics, Inc.
Key Financials
Operating Income
$-91096000
↓ 23.2%
Gross Profit
$130.9M
↑ 22.1%
Net Income
$-60513000
↓ 41.7%
EPS (Diluted)
$-0.11
↓ 266.7%
Revenue
$322.7M
↑ 13.8%
Total Assets
$1.2B
↓ 0.5%
Total Liabilities
$106.8M
↑ 17.6%
Shareholders' Equity
$1.1B
↓ 1.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/3/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 144 | 9/2/2026 | View on SEC |
| 144 | 9/2/2026 | View on SEC |
| 4 | 8/28/2026 | View on SEC |
| 4 | 8/28/2026 | View on SEC |
| 4 | 8/28/2026 | View on SEC |
| 4 | 8/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FLGT |
| Company Name | Fulgent Genetics, Inc. |
| CIK | 1674930 |
| Sector | Services-Medical Laboratories |
| Industry | Accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 8071 |
| SIC Description | Services-Medical Laboratories |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 626-350-0537 |